Literature DB >> 20348384

Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p.

Luiz R Basso1, Charles E Gast, Yuxin Mao, Brian Wong.   

Abstract

A major cause of azole resistance in Candida albicans is overexpression of CDR1, CDR2, and/or MDR1, which encode plasma membrane efflux pumps. To analyze the catalytic properties of these pumps, we used ACT1- and GAL1-regulated expression plasmids to overexpress CDR1, CDR2, or MDR1 in a C. albicans cdr1 cdr2 mdr1-null mutant. When the genes of interest were expressed, the resulting transformants were more resistant to multiple azole antifungals, and accumulated less [(3)H]fluconazole intracellularly, than empty-vector controls. Next, we used a GAL1-regulated dominant negative sec4 allele to cause cytoplasmic accumulation of post-Golgi secretory vesicles (PGVs), and we found that PGVs isolated from CDR1-, CDR2-, or MDR1-overexpressing cells accumulated much more [(3)H]fluconazole than did PGVs from empty-vector controls. The K(m)s (expressed in micromolar concentrations) and V(max)s (expressed in picomoles per milligram of protein per minute), respectively, for [(3)H]fluconazole transport were 0.8 and 0.91 for Cdr1p, 4.3 and 0.52 for Cdr2p, and 3.5 and 0.59 for Mdr1p. [(3)H]fluconazole transport by Cdr1p and Cdr2p required ATP and was unaffected by carbonyl cyanide 3-chlorophenylhydrazone (CCCP), whereas [(3)H]fluconazole transport by Mdr1p did not require ATP and was inhibited by CCCP. [(3)H]fluconazole uptake by all 3 pumps was inhibited by all other azoles tested, with 50% inhibitory concentrations (IC(50)s; expressed as proportions of the [(3)H]fluconazole concentration) of 0.2 to 5.6 for Cdr1p, 0.3 to 3.1 for Cdr2p, and 0.3 to 3.1 for Mdr1p. The methods used in this study may also be useful for studying other plasma membrane transporters in C. albicans and other medically important fungi.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348384      PMCID: PMC2901649          DOI: 10.1128/EC.00355-09

Source DB:  PubMed          Journal:  Eukaryot Cell        ISSN: 1535-9786


  58 in total

Review 1.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Authors:  Dominique Sanglard; Frank C Odds
Journal:  Lancet Infect Dis       Date:  2002-02       Impact factor: 25.071

2.  A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance.

Authors:  Michelle de Micheli; Jacques Bille; Christoph Schueller; Dominique Sanglard
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

3.  Overexpression of a dominant-negative allele of SEC4 inhibits growth and protein secretion in Candida albicans.

Authors:  Y Mao; V F Kalb; B Wong
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

4.  Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters.

Authors:  Christian Gauthier; Sandra Weber; Anne-Marie Alarco; Omar Alqawi; Roni Daoud; Elias Georges; Martine Raymond
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Specificity of drug transport mediated by CaMDR1: a major facilitator of Candida albicans.

Authors:  A Kohli; V Gupta; S Krishnamurthy; S E Hasnain; R Prasad
Journal:  J Biosci       Date:  2001-09       Impact factor: 1.826

6.  Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters.

Authors:  K Nakamura; M Niimi; K Niimi; A R Holmes; J E Yates; A Decottignies; B C Monk; A Goffeau; R D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  ABC transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen Candida albicans are general phospholipid translocators.

Authors:  S Krishnamurthy; B L Dixit; C M Gupta; S Milewski; R Prasad
Journal:  Yeast       Date:  2002-03-15       Impact factor: 3.239

8.  An improved transformation protocol for the human fungal pathogen Candida albicans.

Authors:  Andrea Walther; Jürgen Wendland
Journal:  Curr Genet       Date:  2003-01-30       Impact factor: 3.886

9.  Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains.

Authors:  Nico Dunkel; Julia Blass; P David Rogers; Joachim Morschhäuser
Journal:  Mol Microbiol       Date:  2008-05-27       Impact factor: 3.501

Review 10.  The genetic basis of fluconazole resistance development in Candida albicans.

Authors:  Joachim Morschhäuser
Journal:  Biochim Biophys Acta       Date:  2002-07-18
View more
  14 in total

1.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

2.  Transformation of Candida albicans with a synthetic hygromycin B resistance gene.

Authors:  Luiz R Basso; Ann Bartiss; Yuxin Mao; Charles E Gast; Paulo S R Coelho; Michael Snyder; Brian Wong
Journal:  Yeast       Date:  2010-08-24       Impact factor: 3.239

3.  Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.

Authors:  Scott S Walker; Yiming Xu; Ilias Triantafyllou; Michelle F Waldman; Cara Mendrick; Nathaniel Brown; Paul Mann; Andrew Chau; Reena Patel; Nicholas Bauman; Christine Norris; Barry Antonacci; Maya Gurnani; Anthony Cacciapuoti; Paul M McNicholas; Samuel Wainhaus; R Jason Herr; Rongze Kuang; Robert G Aslanian; Pauline C Ting; Todd A Black
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

Review 4.  The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.

Authors:  M Cuéllar-Cruz; A Vega-González; B Mendoza-Novelo; E López-Romero; E Ruiz-Baca; M A Quintanar-Escorza; J C Villagómez-Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 3.267

5.  Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.

Authors:  Charles E Gast; Luiz R Basso; Igor Bruzual; Brian Wong
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 6.  Multidrug resistance in fungi: regulation of transporter-encoding gene expression.

Authors:  Sanjoy Paul; W Scott Moye-Rowley
Journal:  Front Physiol       Date:  2014-04-16       Impact factor: 4.566

7.  Development and Validation of Simple RP-HPLC Method for Intracellular Determination of Fluconazole Concentration and Its Application to the Study of Candida albicans Azole Resistance.

Authors:  Tigran K Davtyan; Levon A Melikyan; Nune A Nikoyan; Hripsime P Aleksanyan; Nairi G Grigoryan
Journal:  Int J Anal Chem       Date:  2015-12-09       Impact factor: 1.885

8.  Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.

Authors:  Yohsuke Nagayoshi; Taiga Miyazaki; Shintaro Shimamura; Hironobu Nakayama; Asuka Minematsu; Shunsuke Yamauchi; Takahiro Takazono; Shigeki Nakamura; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae; Koichi Izumikawa
Journal:  PLoS One       Date:  2017-07-11       Impact factor: 3.240

9.  Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro study.

Authors:  Ricardo Dias de Castro; Trícia Murielly Pereira Andrade de Souza; Louise Morais Dornelas Bezerra; Gabriela Lacet Silva Ferreira; Edja Maria Melo de Brito Costa; Alessandro Leite Cavalcanti
Journal:  BMC Complement Altern Med       Date:  2015-11-24       Impact factor: 3.659

10.  Exploring the biological roles of Dothideomycetes ABC proteins: Leads from their phylogenetic relationships with functionally-characterized Ascomycetes homologs.

Authors:  Gaurav Dube; Narendra Kadoo; Ramya Prashant
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.